Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265325 · ClinicalTrials.gov registry record · Phase 2
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
A Phase 2 study, sponsored by Kind Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT05265325 is a Phase 2 study that has completed, run by Kind Pharmaceuticals. The registered enrollment target is 175 participants.
The verdict
NCT05265325, a Phase 2 study, has completed, sponsored by Kind Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
Interventions
- DRUG AND017 capsules TIW
- DRUG AND017 capsules QW
- DRUG epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05265325
The ClinicalTrials.gov registry entry for NCT05265325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kind Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AND017 capsules TIW is the first listed.
NCT05265325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05265325 about?
NCT05265325 is a clinical study titled "A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis". This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
What is the current status of trial NCT05265325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2023-05-03. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT05265325?
The interventions under investigation include: AND017 capsules TIW (DRUG), AND017 capsules QW (DRUG), epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars (DRUG).
Who is sponsoring clinical trial NCT05265325?
This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.